Anna Jonášová

1.9k total citations
76 papers, 876 citations indexed

About

Anna Jonášová is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Anna Jonášová has authored 76 papers receiving a total of 876 indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Hematology, 35 papers in Molecular Biology and 20 papers in Genetics. Recurrent topics in Anna Jonášová's work include Acute Myeloid Leukemia Research (57 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Anna Jonášová is often cited by papers focused on Acute Myeloid Leukemia Research (57 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Anna Jonášová collaborates with scholars based in Czechia, United States and Spain. Anna Jonášová's co-authors include Jaroslav Čermák, R Neuwírtová, Magda Šišková, Monika Beličková, Michaela Dostálová Merkerová, Tomáš Stopka, Zdeněk Krejčík, K Michalová, Zuzana Zemanová and E Nečas and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The EMBO Journal.

In The Last Decade

Anna Jonášová

71 papers receiving 853 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Jonášová Czechia	16	588	411	240	196	103	76	876
Naoko Watanabe‐Okochi Japan	15	446 0.8×	481 1.2×	139 0.6×	93 0.5×	101 1.0×	31	809
Sabine Jeromin Germany	12	548 0.9×	321 0.8×	412 1.7×	124 0.6×	79 0.8×	38	764
Sonja Schindela Germany	13	620 1.1×	368 0.9×	314 1.3×	146 0.7×	51 0.5×	25	830
Ruth Knops Netherlands	6	705 1.2×	902 2.2×	283 1.2×	171 0.9×	88 0.9×	12	1.2k
Parva Bhatt United States	3	441 0.8×	289 0.7×	241 1.0×	126 0.6×	94 0.9×	7	632
Marta Pratcorona Spain	14	791 1.3×	572 1.4×	269 1.1×	193 1.0×	54 0.5×	29	1.0k
Dong‐ming Yao China	20	684 1.2×	786 1.9×	201 0.8×	315 1.6×	46 0.4×	61	1.0k
Marion Massop Netherlands	4	650 1.1×	917 2.2×	278 1.2×	168 0.9×	57 0.6×	6	1.2k
Sandra Weißmann Germany	10	525 0.9×	396 1.0×	317 1.3×	116 0.6×	91 0.9×	28	861
Marian Stevens‐Kroef Netherlands	14	396 0.7×	366 0.9×	115 0.5×	133 0.7×	49 0.5×	30	692

Countries citing papers authored by Anna Jonášová

Since Specialization

Citations

This map shows the geographic impact of Anna Jonášová's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Jonášová with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Jonášová more than expected).

Fields of papers citing papers by Anna Jonášová

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Jonášová. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Jonášová. The network helps show where Anna Jonášová may publish in the future.

Co-authorship network of co-authors of Anna Jonášová

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Jonášová. A scholar is included among the top collaborators of Anna Jonášová based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Jonášová. Anna Jonášová is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Krejčík, Zdeněk, Jǐŕı Kléma, Monika Beličková, et al.. (2025). Dysregulation of transposable elements and PIWI-interacting RNAs in myelodysplastic neoplasms. Biomarker Research. 13(1). 13–13. 1 indexed citations

Votavová, Hana, Michaela Dostálová Merkerová, Zdeněk Krejčík, et al.. (2024). Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower‐risk myelodysplastic neoplasms. International Journal of Cancer. 154(9). 1652–1668. 3 indexed citations

Jonášová, Anna, et al.. (2024). Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa. Frontiers in Oncology. 14. 1398331–1398331. 2 indexed citations

Garcia‐Manero, Guillermo, Uwe Platzbecker, Valeria Santini, et al.. (2023). Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).. Journal of Clinical Oncology. 41(16_suppl). 7003–7003.

Beličková, Monika, et al.. (2023). Different Mutations in SF3B1 Gene Have Specific Transcriptomic Characteristics in Myelodysplastic Neoplasms. Blood. 142(Supplement 1). 3218–3218.

Krejčík, Zdeněk, Aleš Holoubek, Jǐŕı Kléma, et al.. (2023). Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B1. Molecular Oncology. 17(12). 2565–2583. 6 indexed citations

Votavová, Hana, Michaela Dostálová Merkerová, Zdeněk Krejčík, et al.. (2022). RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS. Leukemia. 36(7). 1898–1906. 15 indexed citations

Merkerová, Michaela Dostálová, Jǐŕı Kléma, Zdeněk Krejčík, et al.. (2022). Noncoding RNAs and Their Response Predictive Value in Azacitidine-treated Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-related Changes. Cancer Genomics & Proteomics. 19(2). 205–228. 7 indexed citations

Beličková, Monika, Michaela Dostálová Merkerová, Zdeněk Krejčík, et al.. (2021). Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34+ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients. Cancers. 13(9). 2161–2161. 2 indexed citations

10.

Krejčík, Zdeněk, Jǐŕı Kléma, Monika Beličková, et al.. (2020). LncRNA Profiling Reveals That the Deregulation of H19, WT1-AS, TCL6, and LEF1-AS1 Is Associated with Higher-Risk Myelodysplastic Syndrome. Cancers. 12(10). 2726–2726. 21 indexed citations

11.

Krejčík, Zdeněk, Monika Beličková, Jǐŕı Kléma, et al.. (2020). Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome. Cells. 9(4). 794–794. 33 indexed citations

12.

Votavová, Hana, et al.. (2019). Genetic Variant Screening of DNA Repair Genes in Myelodysplastic Syndrome Identifies a Novel Mutation in the <b><i>XRCC2</i></b> Gene. Oncology Research and Treatment. 42(5). 263–268. 3 indexed citations

13.

Merkerová, Michaela Dostálová, et al.. (2018). Relationship between Altered miRNA Expression and DNA Methylation of the DLK1-DIO3 Region in Azacitidine-Treated Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Myelodysplasia-Related Changes. Cells. 7(9). 138–138. 15 indexed citations

14.

Jonášová, Anna, R Neuwírtová, Magda Šišková, et al.. (2018). Lenalidomide treatment in lower risk myelodysplastic syndromes—The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients). Leukemia Research. 69. 12–17. 4 indexed citations

15.

Beličková, Monika, Michaela Dostálová Merkerová, Hana Votavová, et al.. (2016). Up-regulation of ribosomal genes is associated with a poor response to azacitidine in myelodysplasia and related neoplasms. International Journal of Hematology. 104(5). 566–573. 11 indexed citations

16.

Zemanová, Zuzana, Monika Beličková, Jana Březinová, et al.. (2016). Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes. Leukemia Research. 42. 7–12. 21 indexed citations

17.

Jonášová, Anna, Miroslav Barančı́k, Mário Šereš, et al.. (2015). Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome.. PubMed. 34(4). 399–406. 4 indexed citations

18.

Beličková, Monika, Jaroslav Čermák, Michaela Dostálová Merkerová, et al.. (2012). Changes Associated With Lenalidomide Treatment in the Gene Expression Profiles of Patients With Del(5q). Clinical Lymphoma Myeloma & Leukemia. 12(5). 375–383. 7 indexed citations

19.

Neuwírtová, R, Monika Beličková, Jiřina Bartůňková, et al.. (2009). Defective cytotoxicity of T lymphocytes in myelodysplastic syndrome. Experimental Hematology. 37(3). 386–394. 4 indexed citations

20.

Jonášová, Anna, et al.. (1998). Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. British Journal of Haematology. 100(2). 304–309. 163 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact